title: DIFFERENTIAL SUSCEPTIBILITY OF HUMAN SP-B GENETIC VARIANTS ON LUNG INJURY CAUSED BY BACTERIAL PNEUMONIA AND THE EFFECT OF A CHEMICALLY MODIFIED CURCUMIN.
abstract: Staphylococcus aureus is a common cause of nosocomial pneumonia frequently resulting in acute respiratory distress syndrome (ARDS). Surfactant protein B (SP-B) gene expresses two proteins involved in lowering surface tension and host defense. Genotyping studies demonstrate a significant association between human SP-B genetic variants and ARDS. Curcumins have been shown to attenuate host inflammation in many sepsis models. Our hypothesis is that functional differences of SP-B variants and treatment with curcumin (CMC2.24) modulate lung injury in bacterial pneumonia. Humanized transgenic mice, expressing either SP-B T or C allele without mouse SP-B gene, were used. Bioluminescent labeled S. aureus Xen 36 (50 μL) was injected intratracheally to cause pneumonia. Infected mice received daily CMC2.24 (40 mg/kg) or vehicle alone by oral gavage. Dynamic changes of bacteria were monitored using in vivo imaging system. Histological, cellular, and molecular indices of lung injury were studied in infected mice 48 h after infection. In vivo imaging analysis revealed total flux (bacterial number) was higher in the lung of infected SP-B-C mice compared with infected SP-B-T mice (P < 0.05). Infected SP-B-C mice demonstrated increased mortality, lung injury, apoptosis, and NF-κB expression compared with infected SP-B-T mice. Compared with controls, CMC2.24 treatment significantly reduced the following: mortality, total bacterial flux and lung tissue apoptosis, inflammatory cells, NF-κB expression (P < 0.05), and MMPs-2, -9, -12 activities (P < 0.05). We conclude that mice with SP-B-C allele are more susceptible to S. aureus pneumonia than mice with SP-B-T allele, and that CMC2.24 attenuates lung injury thus reducing mortality.
authors: *Department of Surgery, SUNY Upstate Medical University, Syracuse, New York †Department of Emergency Medicine, Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, People's Republic of China ‡Department of Biochemistry and Molecular Biology, Tianjin Medical University, Tianjin, People's Republic of China §Department of Pharmacological Sciences ||Department of Oral Biology and Pathology, State University of New York at Stony Brook, Stony Brook, New York.
authors: Yongan
authors: Y
authors: Xu
authors: Lin
authors: L
authors: Ge
authors: Osama
authors: O
authors: Abdel-Razek
authors: Sumeet
authors: S
authors: Jain
authors: Zhiyong
authors: Z
authors: Liu
authors: Yucai
authors: Y
authors: Hong
authors: Gary
authors: G
authors: Nieman
authors: Francis
authors: F
authors: Johnson
authors: Lorne M
authors: LM
authors: Golub
authors: Robert N
authors: RN
authors: Cooney
authors: Guirong
authors: G
authors: Wang
mesh_terms: D000483:Alleles; D000818:Animals; D003474:Curcumin / Q000494:pharmacology*; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D006801:Humans; D055370:Lung Injury / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D037701:Pulmonary Surfactant-Associated Protein B / Q000235:genetics* / Q000378:metabolism; D013211:Staphylococcus aureus
chemical_list: D037701:Pulmonary Surfactant-Associated Protein B; D003474:Curcumin